NCT05646602View on ClinicalTrials.gov

Focused Shock Wave Therapy Outcomes in Peyronie's Disease and Erectile Dysfunction

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Peyronie DiseasePenile CurvatureErectile Dysfunction
Interventions
DRUG

Collagenase Clostridium Histolyticum

Intralesional injection

DEVICE

Duolith SD1 T-TOP

Delivers low-intensity shockwave therapy, six sessions (once/week) of 2000 shockwaves per session with a constant energy flux density of 0.29 mJ/mm2 and frequency of 3 Hz

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05646602 - Focused Shock Wave Therapy Outcomes in Peyronie's Disease and Erectile Dysfunction | Biotech Hunter | Biotech Hunter